Potential pathogenic role of soluble receptor activator of nuclear factor-κB ligand and osteoprotegerin in patients with pulmonary arterial hypertension

Polskie Archiwum Medycyny Wewnetrznej

Volumn 124, Issue 11, 2014, Pages 579-586

  Jasiewicz, Malgorzata ^a   Knapp, Malgorzata ^a   Waszkiewicz, Ewa ^a   Musial, Wlodzimierz J ^a   Kamiński, Karol A ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Osteoprotegerin; Prognosis; Pulmonary arterial hypertension; sRANKL

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CARBON MONOXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SOLUBLE RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URIC ACID; BIOLOGICAL MARKER;

ADULT; ADVERSE OUTCOME; ARTERIAL OXYGEN SATURATION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DETERIORATION; DISEASE COURSE; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; EXERCISE; FEMALE; FOLLOW UP; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART OUTPUT; HEART RIGHT ATRIUM PRESSURE; HEMODYNAMIC PARAMETERS; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; NEW YORK HEART ASSOCIATION CLASS; PATHOGENESIS; PROGNOSIS; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; TRANSTHORACIC ECHOCARDIOGRAPHY; VENOUS OXYGEN TENSION; BLOOD; COMPARATIVE STUDY; INFLAMMATION; PATHOPHYSIOLOGY;

BIOMARKERS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION; MALE; OSTEOPROTEGERIN;

EID: 84916878206     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2491     Document Type: Article

References (24)

1. Galiè N, Hoeper M, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30: 2493-2537.
2. Perros F, Dorfmüller P, Souza R, et al. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J. 2007; 29: 462-468.
3. Lorenzen JM, Nickel N, Krämer R, et al. Osteopontin in patients with idiopathic pulmonary hypertension. Chest. 2011; 139 :1010-1017.
4. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis. 2002; 45: 173-202.
5. Tuder RM, Marecki JC, Richter A, et al. Pathology of pulmonary hypertension. Clin Chest Med. 2007; 28: 23-42.
6. Jasiewicz M, Kowal K, Kowal-Bielecka O, et al. Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension. Cytokine. 2014; 66: 40-45.
7. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008; 473: 139-146.
8. Lawrie A, Waterman E, Southwood M, et al. Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am J Pathol. 2008; 172: 256-264.
9. Condliffe R, Pickworth JA, Hopkinson K, et al. Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension. Pulm Circ. 2012; 2: 21-27.
10. Janda K, Krzanowski M, Chowaniec E, et al. Osteoprotegerin as a marker of cardiovascular risk in patients on peritoneal dialysis. Pol Arch Med Wewn. 2013; 123: 149-155.
11. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997; 390: 175-179.
12. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab. 2005; 90: 6323-6331.
13. Tachi K, Takami M, Zhao B, et al. Bone morphogenetic protein 2 enhances mouse osteoclast differentiation via increased levels of receptor activator of NF-κB ligand expression in osteoblasts. Cell Tissue Res. 2010; 342: 213-220.
14. Myers J, Bellin D. Ramp exercise protocols for clinical and cardiopulmonary exercise testing. Sports Med. 2000; 30: 23-29.
15. Schwaiblmair M, Faul C, von Scheidt W, Berghaus TM. Ventilatory efficiency testing as prognostic value in patients with pulmonary hypertension. BMC Pulm Med. 2012; 12: 23.
16. Ock S, Ahn J, Lee SH, et al. Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation. Cardiovasc Res. 2012; 94: 105-114.
17. Min JK, Kim YM, Kim SW, et al. TNF-related activation-induced cytokine enhances leukocyte adhesiveness: induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF-kappaB activation in endothelial cells. J Immunol. 2005; 175: 531-540.
18. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997; 96: 526-534.
19. Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J. 1999; 20: 683-693.
20. Anker SD, Clark AL, Teixeira MM, et al. Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol. 1999; 83: 612-615.
21. Baba TT, Ohara-Nemoto Y, Miyazaki T, Nemoto TK. Involvement of geranylgeranylation of Rho and Rac GTPases in adipogenic and RANKL expression, which was inhibited by simvastatin. Cell Biochem Funct. 2013; 31: 652-659.
22. Ueland T, Yndestad A, Oie E, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005; 111: 2461-2468.
23. Omland T, Drazner MH, Ueland T, et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension. 2007; 49: 1392-1398.
24. Adamczyk T, Mizia-Stec K, Mizia M, et al. Biomarkers of calcification and atherosclerosis in patients with degenerative aortic stenosis in relation to concomitant coronary artery disease. Pol Arch Med Wewn. 2012; 122: 14-21.